Compare American Well Corp (AMWL) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Boston Scientific Corporation — how do they compare? American Well Corp trades at $12.46 (market cap $220.94M), while Boston Scientific Corporation trades at $51.6 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 335.8× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| AMWL | BSX | |
|---|---|---|
Market Cap | $220.94M | $74.19B |
Sector | Health | Health |
52-Week High | $13.58 | $108.14 |
52-Week Low | $3.78 | $42.63 |
Enterprise Value | $27.98M | $86.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.54, down 7.66% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows improving financial trends, with revenue declining to $249.33M in 2025 but net losses narrowing significantly to -$95.70M. Recent Q2 2026 earnings beat expectations, and news highlights strategic developments including a key executive appointment at Amazon's healthcare unit.
The outlook suggests cautious optimism as AMWL progresses toward cash-flow breakeven, supported by analyst coverage leaning Hold. Key risks include persistent revenue declines and high cash burn, though improving margins and reduced losses indicate potential for recovery if execution continues.
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
